DDAVP

(Desmopressin)

ApprovedSmall molecule

Desmopressin is used to treat bedwetting in children and nighttime urination in adults, and also helps control bleeding in certain blood disorders and replaces a missing hormone in diabetes insipidus, a condition where the body can't retain water properly.[2] DDAVP is currently approved and in use across 20 indications[4].[1]

DDAVP is one of 251 small molecule programs targeting Enuresis. It is currently in Approved.

Indications

Total Trials

Active Trials

250

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

EnuresisCompleted

Vitamin D DeficiencyActive, not recruiting

Diabetes InsipidusApproved

HemorrhageApproved

Neurohypophyseal Diabetes InsipidusActive, not recruiting

Blood CoagulationActive, not recruiting

Aortic StenosisCompleted

Renal ColicActive, not recruiting

PolyuriaCompleted

LeptospirosisApproved

EnuresisApproved

Completed

Vitamin D DeficiencyPreclinical

Active, not recruiting

Diabetes InsipidusApproved

Approved

HemorrhageApproved

Approved

Neurohypophyseal Diabetes InsipidusPreclinical

Active, not recruiting

Blood CoagulationApproved

Active, not recruiting

Aortic StenosisApproved

Completed

Renal ColicPreclinical

Active, not recruiting

PolyuriaApproved

Completed

LeptospirosisApproved

Approved

Showing 10 of 19 indications

Competition

Competitive Landscape

91 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

DDAVP

Ferring

Approved

1 2

Campath

GGenzyme, a Sanofi Company

Phase 3

14 3

Ritalin

Novartis

Phase 3

2 4

Toradol

JJavelin Pharmaceuticals

Phase 3

2 5

Fludara

Sanofi

Phase 2

10 6

Cellcept

Roche

Phase 2

6 7

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

4 8

PIASKY

Roche

Phase 3

2 9

Tepadina

Jazz Pharmaceuticals

Phase 2

4 10

Rapamune

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Bleeding

NCT06337838

Q3 2027

PreclinicalRecruiting

Nocturnal Enuresis

NCT07776977

Q1 2028

Phase 3Recruiting

Hyponatremia

NCT06020495

Q1 2029

Phase 2Recruiting

Cushing Syndrome

NCT06635629

Clinical

Trials by Indication[1]

Desmopressin10 trials

Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients

Completed· Ferring logo

Ferring·Phase 3·NCT01223937·268 enrolled

Desmopressin for Bleeding Related to Low Body Temperature

Unknown status·TThe University of Hong Kong·Phase 4·NCT00902057·48 enrolled

Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older

Terminated·MMount Sinai Hospital, Canada·Phase 2/3·NCT02262936·4 enrolled

Show 7 more trials

Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures

Completed· Ferring logo

Ferring··NCT02368730·23 enrolled

Desmopressin for Bedwetting in Children With SCD

Terminated·MMontefiore Medical Center·Phase 4·NCT04420585·8 enrolled

Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

Completed· Ferring logo

Ferring·Phase 3·NCT01262456·395 enrolled

Desmopressin Response in the Young

Completed· Ferring logo

Ferring·Phase 3·NCT00230594·132 enrolled

Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation

Completed·UUniversity Hospital, Ghent·Phase 4·NCT01036841·24 enrolled

Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies

Enrolling by invitation·HHospital de Clinicas de Porto Alegre·Phase 4·NCT06622187·96 enrolled

Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population

Completed·UUniversity Ghent·Phase 4·NCT02584231·25 enrolled

Polyuria6 trials

Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects

Completed· Ferring logo

Ferring·Phase 3·NCT02905682·190 enrolled

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

Completed· Ferring logo

Ferring·Phase 2·NCT03201419·302 enrolled

Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity

Completed·SSamsung Medical Center·Phase 4·NCT00902655·103 enrolled

Show 3 more trials

Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects

Completed· Ferring logo

Ferring·Phase 3·NCT02904759·342 enrolled

Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study

Completed·UUniversity Hospital, Ghent·Phase 4·NCT01435083·50 enrolled

Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study

Completed·UUniversity Hospital, Ghent·Phase 4·NCT01439997·5 enrolled

Enuresis6 trials

Desmopressin for Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Bladder Reconstruction

Unknown status·RRabin Medical Center·Phase 4·NCT01582542·50 enrolled

Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis.

Unknown status·FFayoum University Hospital·N/A·NCT06185361·60 enrolled

Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis

Recruiting·—·N/A·NCT06285006·50 enrolled

Show 3 more trials

Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis

Unknown status·—·N/A·NCT05617664·150 enrolled

The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings.

Completed·UUniversity of Aarhus·Phase 4·NCT03389412·324 enrolled

Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis

Completed· Ferring logo

Ferring·Phase 3·NCT01078753·89 enrolled

Hemophilia A3 trials

Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A

Unknown status·GGroupe Maladies hémorragiques de Bretagne··NCT05628558·800 enrolled

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

Completed·EEmory University·Phase 1·NCT02506023·2 enrolled

Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A

Completed·GGroupe Maladies hémorragiques de Bretagne··NCT06020456·361 enrolled

Nocturia3 trials

Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)

Completed· Ferring logo

Ferring··NCT04329975·1,087 enrolled

Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary

Completed· Ferring logo

Ferring·Phase 3·NCT01552343·56 enrolled

Study of Minirin Melt® in Adult Patients With Nocturia

Terminated· Ferring logo

Ferring··NCT03089073·835 enrolled

33 more indications

Blood Coagulation1 trial

Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve Surgery

Unknown status·IInstituto do Coracao·Phase 4·NCT03343418·108 enrolled

Prostate Cancer1 trial

Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer

Unknown status·SSunnybrook Health Sciences Centre·Phase 1·NCT04113005·10 enrolled

Sleep1 trial

Daytime Impact Sleep Study

Terminated· Ferring logo

Ferring·Phase 2·NCT01779466·5 enrolled

Surgical Field1 trial

Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery

Completed·TTao Zhang·Phase 4·NCT02125188·60 enrolled

Colorectal Cancer1 trial

Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding

Completed·LLaboratorio Elea Phoenix S.A.·Phase 2·NCT01623206·30 enrolled

Renal Colic1 trial

Intranasal Desmopressin vs IV Ketorolac in Renal Colic Pain Control

Completed·SShahid Beheshti University of Medical Sciences·N/A·NCT02937896·40 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)

Completed· Ferring logo

Ferring··NCT00902265·138 enrolled

Trial1 trial

Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo

Completed· Ferring logo

Ferring·Phase 2·NCT01184859·116 enrolled

Nephrectomy1 trial

To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors

Withdrawn·UUniversity of Kansas Medical Center·Phase 4·NCT03676361

Obstructive Sleep Apnoea1 trial

Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients

Terminated·—·Phase 3·NCT01530451·9 enrolled

Breast Cancer1 trial

Perioperative Use of Desmopressin (DDAVP) in Breast Cancer

Completed·LLaboratorio Elea Phoenix S.A.·Phase 2·NCT01606072·21 enrolled

Vitamin D Deficiency1 trial

Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency

Completed·—·N/A·NCT07292753·90 enrolled

Children1 trial

Study on Chinese and Western Medicine in MNE Children

Completed·—·N/A·NCT03733873·400 enrolled

Perioperative Bleeding1 trial

Analysis of the Clinical Efficacy of Intravenous Application of Hemostatic Drugs in Improving the Clarity of Vision Under Endoscope, Perioperative Bleeding Volume and Anti-inflammatory Effect of Spinal Endoscopic Lumbar Fusion

Not yet recruiting·—·Phase 4·NCT06255366·126 enrolled

Sickle Cell Disease1 trial

Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

Terminated·MMontefiore Medical Center··NCT02636387·14 enrolled

Diabetes Insipidus1 trial

Study of Novel Types of Familial Diabetes Insipidus

Unknown status·NNational Center for Research Resources (NCRR)··NCT00004364·5 enrolled

Kidney Biopsy1 trial

Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin

Recruiting·MMedical University of Bialystok·Phase 3·NCT05467033·424 enrolled

After Cardiac Surgery1 trial

Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery

Terminated·SSt. Olavs Hospital·Phase 4·NCT00885924·17 enrolled

Neurohypophyseal Diabetes Insipidus1 trial

Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus

Completed·NNational Center for Research Resources (NCRR)··NCT00004363

Overactive Bladder1 trial

Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women

Completed· Ferring logo

Ferring·Phase 2·NCT01729819·106 enrolled

Stroke1 trial

Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage

Completed·UUniversity of Nottingham·Phase 2·NCT03696121·54 enrolled

Bleeding1 trial

Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial

Recruiting·HHamilton Health Sciences Corporation·Phase 3·NCT06337838·100 enrolled

Hypertension1 trial

Treatment of Supine Hypertension in Autonomic Failure

Completed·VVanderbilt University·Phase 1·NCT00223717·152 enrolled

Cardiac Surgery1 trial

Desmopressin in Cardiac Surgery

Completed·UUniversità Vita-Salute San Raffaele·Phase 4·NCT00337766

Sinus Surgery1 trial

Nasal Desmopressin Versus Oral Bisoprolol for Controlling Bleeding During Endoscopic Sinus Surgery

Completed·ZZagazig University·Phase 2·NCT05430048·100 enrolled

Combination Therapy1 trial

Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE

Recruiting·MMansoura University·Phase 3·NCT07199894·120 enrolled

Aortic Stenosis1 trial

Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery

Completed·PPontificia Universidad Catolica de Chile·Phase 4·NCT01994330·13 enrolled

Cirrhosis1 trial

Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

Completed·IIcahn School of Medicine at Mount Sinai·N/A·NCT00816127·36 enrolled

Hyponatremia1 trial

Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia: a Multicenter Open-label Randomized Controlled Trial

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06020495·260 enrolled

Cushing syndrome1 trial

Phase II Prospective Evaluation of Desmopressin Stimulation Test Performance in ACTH-dependent Cushing s Syndrome

Recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT06635629·140 enrolled

Nocturnal Enuresis1 trial

Effect of Bedtime Digital-Device Restriction on the Therapeutic Response to Desmopressin in Children With Primary Monosymptomatic Nocturnal Enuresis: A Randomized Controlled Trial

Recruiting·AAl-Azhar University·Preclinical·NCT07776977·140 enrolled

Craniopharyngioma1 trial

A Randomized, Controlled, Open-Label Clinical Trial of Prophylactic Intraoperative Desmopressin (dDAVP) in Patients Undergoing Surgery for Complex Sellar Region Tumors

Enrolling by invitation·ZZhaoyun Zhang·Approved·NCT07712328·152 enrolled

Unspecified1 trial

A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers

Completed·BBand Therapeutics·Phase 1·NCT04103034·112 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

DDAVP

NDA NDA017922

Mar 30, 1984

DDAVP

NDA NDA018938

Dec 20, 1984

DDAVP

NDA NDA018938

Nov 7, 1985

DDAVP

NDA NDA018938

Apr 3, 1990

DDAVP

NDA NDA018938

Dec 26, 1990

CONCENTRAID

NDA NDA019776

May 12, 1993

DDAVP

NDA NDA018938

Jan 11, 1994

DDAVP

NDA NDA018938

Mar 7, 1994

STIMATE

NDA NDA020355

Mar 13, 1995

DDAVP

NDA NDA018938

Sep 6, 1995

DDAVP

NDA NDA019955

Mar 25, 1998

DDAVP

NDA NDA019955

Aug 17, 1998

DDAVP

NDA NDA018938

Sep 24, 1999

DDAVP

NDA NDA019955

Oct 31, 2000

DDAVP

NDA NDA019955

Aug 8, 2002

DDAVP

NDA NDA018938

Sep 16, 2002

MINIRIN

NDA NDA021333

Nov 12, 2003

DDAVP

NDA NDA019955

Nov 12, 2003

DDAVP

NDA NDA018938

Nov 10, 2005

DDAVP

NDA NDA019955

Nov 10, 2005

DDAVP

NDA NDA018938

Oct 26, 2007

DDAVP

NDA NDA018938

Oct 26, 2007

DDAVP

NDA NDA019955

May 8, 2008

DESMOPRESSIN ACETATE

NDA NDA021795

Feb 28, 2014

DDAVP

NDA NDA019955

Nov 5, 2015

DDAVP

NDA NDA018938

Mar 3, 2017

NOCTIVA

NDA NDA201656

Mar 22, 2018

DDAVP

NDA NDA018938

Jun 21, 2018

NOCDURNA

NDA NDA022517

Jul 21, 2022

DDAVP

NDA NDA018938

Feb 25, 2026

DESMODA

NDA NDA219873

Sources

References

[1]
ClinicalTrials.gov — 61 trial records for Desmopressin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — DDAVP drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Desmopressin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Desmopressin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA219873). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for DDAVP. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Ferring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Vasopressin Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Ferring

Patent Landscape[6]

Patent Cliff

May 21, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11963995May 21, 2029

11020448May 21, 2029

10137167May 21, 2029

9974826Apr 13, 2030

12090190Jun 15, 2030

4 more patents

11419914Jun 15, 2030

9539302Jun 15, 2030

12343372Apr 3, 2044

12214010Apr 3, 2044

DDAVP

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q1 2028

Q1 2029

Trials by Indication[1]

Desmopressin10 trials

Polyuria6 trials

Enuresis6 trials

Hemophilia A3 trials

Nocturia3 trials

Blood Coagulation1 trial

Prostate Cancer1 trial

Sleep1 trial

Surgical Field1 trial

Colorectal Cancer1 trial

Renal Colic1 trial

Efficacy and Safety1 trial

Trial1 trial

Nephrectomy1 trial

Obstructive Sleep Apnoea1 trial

Breast Cancer1 trial

Vitamin D Deficiency1 trial

Children1 trial

Perioperative Bleeding1 trial

Sickle Cell Disease1 trial

Diabetes Insipidus1 trial

Kidney Biopsy1 trial

After Cardiac Surgery1 trial

Neurohypophyseal Diabetes Insipidus1 trial

Overactive Bladder1 trial

Stroke1 trial

Bleeding1 trial

Hypertension1 trial

Cardiac Surgery1 trial

Sinus Surgery1 trial

Combination Therapy1 trial

Aortic Stenosis1 trial

Cirrhosis1 trial

Hyponatremia1 trial

Cushing syndrome1 trial

Nocturnal Enuresis1 trial

Craniopharyngioma1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News